FDA commissioner says agency cannot be the only regulator of AI in digital healthnews2024-01-10T22:26:17+00:00January 10th, 2024|Endpoints News|
#JPM24: bluebird is still looking for more financing as it brings sickle cell therapy to marketnews2024-01-10T22:15:31+00:00January 10th, 2024|Endpoints News|
#JPM24: Moderna is ‘growing up,’ preparing for losses and charting a path back to profitsnews2024-01-10T17:42:43+00:00January 10th, 2024|Endpoints News|
#JPM24: Catalent touts GLP-1 manufacturing; Telix grows radiopharma capacity; Arcturus expands in Japannews2024-01-10T17:04:31+00:00January 10th, 2024|Endpoints News|
FDA’s CBER chief hints at expanding Sarepta’s gene therapy label, sends stock up 25%news2024-01-10T16:17:31+00:00January 10th, 2024|Endpoints News|
Aclaris’ mixed PhIIb eczema data; Amgen licenses Xeris’ tech; Bolden Tx secures fundingnews2024-01-10T16:11:01+00:00January 10th, 2024|Endpoints News|
Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyoutnews2024-01-10T16:01:11+00:00January 10th, 2024|Endpoints News|
C4 Therapeutics cuts staff, restructures to focus on lead protein degradation programs, discovery pactsnews2024-01-10T13:15:23+00:00January 10th, 2024|Endpoints News|
LinkedUp, TianTi end legal dispute with Adimab over yeast-based antibody platformnews2024-01-10T12:29:13+00:00January 10th, 2024|Endpoints News|
CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinicnews2024-01-10T11:45:35+00:00January 10th, 2024|Endpoints News|
